 |
|
NICE gives backing for the use of advanced biological therapies to treat severe psoriasis
July 27, 2006The UK National Institute for Health and Clinical Excellence (NICE) has today issued guidance for the use of the targeted biological therapies, Enbrel® (etanercept) and Raptiva® (efalizumab), to treat adult patients with severe plaque psoriasis. However, top experts have expressed their concerns that many patients across Europe could still be denied treatment with this newest class of drugs due to funding issues.
NICE's announcement comes as welcome relief to the thousands of UK patients who have exhausted current available treatment options and failed to sustain a long-term benefit. It is a positive sign for patients throughout Europe, whose healthcare systems are influenced by NICE decisions. Leeroy Blake in England was fortunate enough to be offered treatment with a biological therapy, after years of trying every other available psoriasis treatment: "For many years, I tried every suitable treatment but nothing seemed to relieve the painful itching. As the itching got worse, I would get more stressed and this only made my condition worse. Following a treatment review with my doctor, I was prescribed a biological therapy and for the first time since developing psoriasis, my skin started to clear and my confidence came back. This treatment might not be suitable for everyone with severe psoriasis, but I think that it's important that patients at least discuss this option with their doctor".
Latest research has dismissed the preconception that psoriasis is merely a skin complaint, with recent data showing that severe psoriasis can affect a patient's quality of life to a similar extent as other prevalent chronic diseases such as diabetes and even heart diseases .
In addition to the impact on a patient's appearance, up to 30% of patients with psoriasis have been reported to have psoriatic arthritis, which causes pain, stiffness and swelling in and around the joints. Coinciding with its decision on the use of biological therapies in moderate to severe psoriasis, NICE has also given its backing for the NHS to use Enbrel and Remicade® (infliximab) to treat patients with severe, active psoriatic arthritis. Professor Robert Moots, Professor of Rheumatology at the University of Liverpool, UK welcomes this guidance commenting, "the NICE guidance is a positive step forward for those patients whose condition is severe enough to warrant treatment with biologic therapies" adding that "the onus is now on NHS trusts to take note of this recent recommendation and ensure that the necessary funding is in place to allow patients access to these much-needed therapies."
This latest NICE guidance should now ensure that for adult patients with severe plaque psoriasis, who have failed on standard therapies, these new treatment options can now be made available. Lars Ettarp, President of the International Federation of Psoriasis Associations (IFPA) underlines that "psoriasis is a systemic disease and that IFPA welcomes the new therapies in the treatment of severe psoriasis/psoriatic arthritis. The national healthcare providers must now make funding for these new drugs available in order to help these really sick persons."
Professor Knud Kragballe, Department of Dermatology, Ã-rhus University Hospital in Denmark, has echoed this call: "Health care providers throughout Europe should take note of these recommendations and ensure that necessary funding is in place to allow access to biological therapies. Psoriasis can be highly debilitating and painful condition. If patients fulfill the criteria for a biological therapy then, I believe, it is important that treatment is started with minimal delay.5"
Stevo Knezevic, MD, PhD, chief medical officer of Wyeth Europa commented: "This endorsement of biological therapies is excellent news for psoriatic patients across Europe and the healthcare professionals who care for them. It is now vital that healthcare providers take note of the positive NICE decision, the opinion of dermatologists and the needs of psoriatic patients, and make funding for these therapies available as quickly as possible."
Patients who would like to find out more about biological therapy are advised to talk to their dermatologist.
In the European Union, Enbrel® is approved for the treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA (Psoralen (a light-sensitizing medication) combined with exposure to ultraviolet light A (UVA).2 Enbrel is also approved for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate.2
Physicians in Europe have become familiar with the benefits and long-term tolerability profile of ENBREL since it became commercially available over six years ago. More than 400,000 patients have been treated worldwide across indications. Enbrel is a recombinant human tumour necrosis factor (TNF) receptor fusion protein that inhibits the activity of TNF. TNF is a cytokine that is released from T lymphocytes; it mediates inflammation and modulates the cellular immune response2. Enbrel is also indicated for treatment of the following: 2
- Severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.
- Active Juvenile Idiopathic Arthritis in children aged 4 to 17 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Enbrel has not been studied in children aged less than 4 years.
- Severe active ankylosing spondylitis in adults who have had an inadequate response to conventional therapy.
Since the product was first introduced, serious infections, some involving death, have been reported in patients using ENBREL. Patients should tell their doctor if they currently have an infection or are prone to getting infections. Patients should not start ENBREL if they have an infection of any type or an allergy to ENBREL or its components. ENBREL should be used with caution in patients prone to infection.
There have been reports of serious nervous-system disorders such as multiple sclerosis and/or inflammation of the nerves of the eyes . Patients should inform their doctor if they have ever had any of these disorders or if they develop them after starting ENBREL9. Patients should also tell their doctor if they have ever been treated for heart failure. There also have been rare reports of serious blood disorders, some involving death.
Patients should contact their doctor immediately if they develop symptoms such as persistent fever, bruising, bleeding, or paleness. It is unclear if ENBREL has caused these nervous-system or blood disorders. If a patient's doctor confirms serious blood problems, patients may need to stop using ENBREL.
Ketchum
In addition to the impact on a patient's appearance, up to 30% of patients with psoriasis have been reported to have psoriatic arthritis, which causes pain, stiffness and swelling in and around the joints. Coinciding with its decision on the use of biological therapies in moderate to severe psoriasis, NICE has also given its backing for the NHS to use Enbrel and Remicade® (infliximab) to treat patients with severe, active psoriatic arthritis. Professor Robert Moots, Professor of Rheumatology at the University of Liverpool, UK welcomes this guidance commenting, "the NICE guidance is a positive step forward for those patients whose condition is severe enough to warrant treatment with biologic therapies" adding that "the onus is now on NHS trusts to take note of this recent recommendation and ensure that the necessary funding is in place to allow patients access to these much-needed therapies."
This latest NICE guidance should now ensure that for adult patients with severe plaque psoriasis, who have failed on standard therapies, these new treatment options can now be made available. Lars Ettarp, President of the International Federation of Psoriasis Associations (IFPA) underlines that "psoriasis is a systemic disease and that IFPA welcomes the new therapies in the treatment of severe psoriasis/psoriatic arthritis. The national healthcare providers must now make funding for these new drugs available in order to help these really sick persons."
Professor Knud Kragballe, Department of Dermatology, Ã-rhus University Hospital in Denmark, has echoed this call: "Health care providers throughout Europe should take note of these recommendations and ensure that necessary funding is in place to allow access to biological therapies. Psoriasis can be highly debilitating and painful condition. If patients fulfill the criteria for a biological therapy then, I believe, it is important that treatment is started with minimal delay.5"
Stevo Knezevic, MD, PhD, chief medical officer of Wyeth Europa commented: "This endorsement of biological therapies is excellent news for psoriatic patients across Europe and the healthcare professionals who care for them. It is now vital that healthcare providers take note of the positive NICE decision, the opinion of dermatologists and the needs of psoriatic patients, and make funding for these therapies available as quickly as possible."
Patients who would like to find out more about biological therapy are advised to talk to their dermatologist.
In the European Union, Enbrel® is approved for the treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA (Psoralen (a light-sensitizing medication) combined with exposure to ultraviolet light A (UVA).2 Enbrel is also approved for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate.2
Physicians in Europe have become familiar with the benefits and long-term tolerability profile of ENBREL since it became commercially available over six years ago. More than 400,000 patients have been treated worldwide across indications. Enbrel is a recombinant human tumour necrosis factor (TNF) receptor fusion protein that inhibits the activity of TNF. TNF is a cytokine that is released from T lymphocytes; it mediates inflammation and modulates the cellular immune response2. Enbrel is also indicated for treatment of the following: 2
- Severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.
- Active Juvenile Idiopathic Arthritis in children aged 4 to 17 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Enbrel has not been studied in children aged less than 4 years.
- Severe active ankylosing spondylitis in adults who have had an inadequate response to conventional therapy.
Since the product was first introduced, serious infections, some involving death, have been reported in patients using ENBREL. Patients should tell their doctor if they currently have an infection or are prone to getting infections. Patients should not start ENBREL if they have an infection of any type or an allergy to ENBREL or its components. ENBREL should be used with caution in patients prone to infection.
There have been reports of serious nervous-system disorders such as multiple sclerosis and/or inflammation of the nerves of the eyes . Patients should inform their doctor if they have ever had any of these disorders or if they develop them after starting ENBREL9. Patients should also tell their doctor if they have ever been treated for heart failure. There also have been rare reports of serious blood disorders, some involving death.
Patients should contact their doctor immediately if they develop symptoms such as persistent fever, bruising, bleeding, or paleness. It is unclear if ENBREL has caused these nervous-system or blood disorders. If a patient's doctor confirms serious blood problems, patients may need to stop using ENBREL.
Ketchum
Psoriasis Current Events and Psoriasis News RSSMultiple health concerns surface as winter, vitamin D deficiences arrive
A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic."
Curry-cure? Spicing up the effectiveness of a potential disease-fighter
Scientists are reporting development of a nano-size capsule that boosts the body's uptake of curcumin, an ingredient in yellow curry now being evaluated in clinical trials for treatment of several diseases.
Skin-disease patients show brain immunity to faces of disgust
People with psoriasis - an often distressing dermatological condition that causes lesions and red scaly patches on the skin - are less likely to react to looks of disgust by others than people without the condition, new research has found.
Gene variation is 'major genetic determinant of psoriasis'
A specific genetic region that has been increasingly identified as the strongest genetic link to psoriasis has an even more significant role in the chronic skin disease than has been suspected, University of Utah medical researchers show in a new study.
Drug rescues memory lost to Alzheimer's disease
A drug similar to one used in clinical trials for treatment of rheumatoid arthritis and psoriasis has been found to rescue memory in mice exhibiting Alzheimer's symptoms.
Post-transplant combo can replace toxic immune-suppressing drugs in monkeys
Transplant patients rely on drugs to prevent graft rejection, but at the cost of serious side effects.
Psoriasis associated with cardiovascular disease and increased mortality
The skin disease psoriasis is associated with atherosclerosis (a buildup of plaque in the arteries) characterized by an increased prevalence of ischemic heart disease, cerebrovascular disease, peripheral artery disease and an increased risk of death.
Scientists discover new genetic immune disorder in children
Your immune system plays an important function in your health-it protects you against viruses, bacteria, and other toxins that can cause disease.
Study finds unexpected bacterial diversity on human skin
The health of our skin - one of the body's first lines of defense against illness and injury - depends upon the delicate balance between our own cells and the millions of bacteria and other one-celled microbes that live on its surface.
Vitamin D may halt lung function decline in asthma and COPD
Vitamin D may slow the progressive decline in the ability to breathe that can occur in people with asthma as a result of human airway smooth muscle (HASM) proliferation, according to researchers at the University of Pennsylvania.
More Psoriasis Current Events and Psoriasis News Articles
 |
Healing Psoriasis: The Natural Alternative by John Pagano (Author) A leading researcher shares natural remedies for psoriasis According to the National Psoriasis Foundation, at least seven million people in the U.S. and more than 100 million worldwide suffer from this chronic skin disease. This book outlines Dr. Pagano's natural, drug-free treatment regimen that can alleviate, control, and even heal psoriasis without steroid creams, tar baths, injections, or ultraviolet treatments. Healing Psoriasis outlines a healthy diet and lifestyle and includes case histories, photos, recipes, and a chapter on eczema. John O. A. Pagano, DC (Englewood Cliffs, NJ), is a chiropractic physician who has conducted psoriasis research for more than 40 years. He has been a featured guest on CNBC, ABC, and Health Talk with Dr. Ronald Hoffman, and... |
 |
Loma Lux Homeopathic Medicine, Psoriasis, 8 fl oz (237 ml) by Loma Lux For relief from the scaling, itching and redness of Psoriasis and Seborrhea. Take orally. 2% Alcohol. Dermatologist Steven A. Smith, MD, developed the Loma Lux Psoriasis formula & has proven its effectiveness in treating thousands of patients for psoriasis and seborrheic dermatitis. Get relief from scaling, flaking, redness, pain and itching with Loma Lux Psoriasis. I spent hundreds of dollars on creams from the doctor; nothing worked. A miracle came in Loma Lux Psoriasis! before the first month was up I noticed a big difference in my psoriasis. My skin cleared with continued use. Loma Lux is dedicated to promote worldwide health and wholeness using natural, low dose, low side effect treatments, bringing freedom from chronic diseases. |
 |
Psoriasis Healing from the Inside Out by Heather J. Ferris (Author) "At last a beautifully written book on how to manage this difficult external condition by internal means. I will recommend this book to all my patients with psoriasis." Dr Stephen Falkner MB., Ch.B. Psoriasis Healing from the Inside Out is an important book for people with psoriasis and other conditions, who feel controlled by their diseases. The author Heather Ferris shares her own profound (and simple) experiences with healing addressing issues of body, mind and spirit. She provides practical techniques and opportunities to reflect on individual situations. The author's warm and caring style is evident as she invites us to experience a more peaceful inner environment. Reading this book reminds us to live full, healthy lives. |
 |
Adovia Natural Dead Sea Mud Soap - Great for Eczema, Psoriasis or Acne! by Adovia Mineral Skin Care Our All Natural Black Mud Soap contains a unique combination of Dead Sea minerals derived from Dead Sea Mud. This effective mud soap removes dirt and cleanses your skin, while simultaneously infusing it with minerals essential to keeping your skin hydrated and moisturized. Our Dead Sea mud soap is enriched with century old Dead Sea mud, leaving your skin cleansed and nourished. As more people are learning about the healing and beauty effects of black mud from The Dead Sea, this soap is becoming a very popular choice for skin care conscious people. |
 |
Your Healing Diet: A Quick Guide to Reversing Psoriasis and Chronic Diseases with Healing Foods by Deirdre Earls RD LD (Author) 'Your Healing Diet: A Quick Guide to Reversing Psoriasis and Chronic Diseases with Healing Foods' is a handbook written by Deirdre Earls, RD, LD, to make it faster and easier to eat in a way that enables the body to heal itself. A short guidebook which was designed to be very user-friendly, it also explains how food can create and reverse disease. In essense, the book distills common threads of success amongst several healing diets like Macrobiotics, Raw Foods, Alkalizing, Cancer and Heart Disease Prevention, Anti-Aging and Anti-inflammatory Diets. Then it demonstrates how you can easily incorporate healing habits into your busy lifestyle. Special segments discuss healing principles and what to expect when healing naturally. Whether or not you're an Austinite, you'll also find... |
 |
Oxipor VHC Psoriasis Lotion, Coal Tar Solution, 4-Ounce Bottle by Oxipor Oxipor psoriasis lotion controls itching, and relieves redness and scaling. |
 |
The Psoriasis Cure: A Drug-Free Guide to Stopping & Reversing the Symptoms of Psoriasis by Lisa LeVan (Author) This book offers hope for those who suffer from this debilitating systemic disease. Beyond causing scaly red patches on the skin, psoriasis can result in aching joints, listlessness, and arthritis. Featuring a nutritional approach to treatment, this book teaches the patient to eliminate allergic reactions and to add specific supplements to the diet. |
 |
Mg 217 Intensive Strength Medicated Tar Ointment for Psoriasis - 3.8 Oz by Mg 217 Mg 217 Intensive Strength Medicated Tar Ointment for Psoriasis is specially formulated to control the itching, redness and scaling from skin psoriasis. |
 |
Psoriasis: Everything You Need to Know (Your Personal Health) by Dr Richard G.B. Langley (Author) Helpful advice for relief of a chronic condition that affects millions. Psoriasis is a chronic inflammatory, non-contagious skin disease. Characterized by itchy, thick and raised red areas of skin covered with silvery-white scales, psoriasis affects 1 in 50 adults. This affliction makes it one of the world's most common skin disorders. Appearing at any age, it can affect relationships, the ability to work and to enjoy leisure activities. Psoriasis is a straightforward book about an all too common problem. The information is presented in clear, understandable terms for non-medical readers, covering: - Causes - Psychosocial effects - Diagnosis - Treatment options - Psoriatic arthritis - Psoriasis in children. Psoriasis includes line drawings, case studies, a... |
 |
Psoriasis: The Real Way Out: A Self-Education Guide to Complete Natural Healing by Jerry G. Scott R.N.C. (Author) This is a book for the determined, not for the quick fix crowd. A clear understanding of the underlying causes of psoriasis is presented, one that flies in the face of current drug-oriented treatments, nevertheless one that recognizes the causes and alleviation of psoriasis that have been known for decades. Leading edge strategies are also revealed, and resources are listed. The book is blunt, and does not coddle the reader. Rather, it requires participation if the reader is to be healed of the condition, and very specific solutions are offered in a comprehensive plan of action. Uniquely, the author offers his personal help when readers are registered through links that are provided in the book. |
| © 2009 BrightSurf.com |